May 21, 2024
Global Mycoplasma Testing Market

Global Mycoplasma Testing Market Is Driven By Growing Adoption Of Personalized Medicine

Mycoplasmas are the smallest bacteria lacking cell walls, which can contaminate cell cultures and produce altered experimental results. Mycoplasma testing helps to detect and eliminate such contaminations. The market has witnessed significant growth due to the increasing outsourcing of manufacturing activities by pharmaceutical companies and growing demand for novel drug development.

The Global Mycoplasma Testing Market Sizeis estimated to be valued at US$ 997.8 MN in 2024 and is expected to exhibit a CAGR of 9.7% over the forecast period 2024 to 2031.

Mycoplasma testing products such as kits & reagents, services, and instruments are used at various stages of drug development and manufacturing to ensure safety and efficacy of biologics and cell therapy products. This has propelled the adoption of mycoplasma testing in the life sciences industry.

Key Takeaways
Key players operating in the Global Mycoplasma Testing Market Size are Charles River Laboratories International, Merck KGaA, Lonza Group Ltd, Roche Diagnostics, Thermo Fisher Scientific, Merck, InvivoGen, Creative Bioarray.

The growing demand for advanced biopharmaceuticals and cell therapies has boosted the mycoplasma testing market. Stringent regulations regarding sterility and purity of manufactured products mandate regular mycoplasma screening. This is expected to drive the need for reliable testing solutions in the coming years.

Geographic expansion into emerging markets and increasing collaborations with CDMOs are some key strategies adopted by market players. This is anticipated to further aid the global proliferation of the mycoplasma testing market during the forecast period.

Market Key Trends
One of the key trends in the mycoplasma testing market is the technological advancement of platforms. Players are increasingly focusing on the development of rapid, sensitive, and specific testing methods. This includes polymerase chain reaction (PCR)-based tests and digital PCR allowing detection within 24 hours. Automation of routine tests is another area attracting innovative product development activities. These new methods help improve process efficiency in the pharmaceutical industry.

Porter’s Analysis
Threat of new entrants: Medium threat as requires high initial investment and also regulatory approvals are required.
Bargaining power of buyers: Medium as buyers have some bargaining power being large organizations looking for quality standards but limited alternatives.
Bargaining power of suppliers: Low to medium as suppliers have specialized testing reagents and equipment suppliers but buyers can choose from existing big players.
Threat of new substitutes: Low threat as no close substitute for mycoplasma testing in biotechnology and pharmaceutical industries.
Competitive rivalry: High among existing big players to gain market share and due to regulated nature, emphasis is on service quality, reliability and certification.

Geographical Regions
North America region accounts for the largest share in global mycoplasma testing market in terms of value primarily due to stringent regulatory norms and increasing research activities in biotechnology and pharmaceutical industries in the US and Canada.

Asia Pacific region is expected to witness the fastest growth during the forecast period majorly attributed to increasing outsourcing of clinical trials to countries like China and India along with growth in biologics manufacturing in countries like China, India and South Korea. Rising awareness about quality standards and increasing healthcare expenditure is further contributing to the market growth in the region.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it